Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Infinity Pharmaceuti (INFI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 117,679
  • Shares Outstanding, K 56,850
  • Annual Sales, $ 6,000 K
  • Annual Income, $ -41,830 K
  • 36-Month Beta 2.15
  • Price/Sales 18.76
  • Price/Cash Flow N/A
  • Price/Book 2.44

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.17
  • Number of Estimates 4
  • High Estimate -0.12
  • Low Estimate -0.21
  • Prior Year -0.14
  • Growth Rate Est. (year over year) -21.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.70 +21.76%
on 07/30/18
2.22 -6.76%
on 08/10/18
+0.03 (+1.47%)
since 07/13/18
3-Month
1.65 +25.45%
on 06/21/18
2.24 -7.59%
on 06/26/18
+0.01 (+0.49%)
since 05/14/18
52-Week
0.93 +122.58%
on 08/29/17
3.75 -44.80%
on 10/12/17
+0.96 (+86.49%)
since 08/14/17

Most Recent Stories

More News
Infinity (INFI) Posts Narrower-Than-Expected Loss in Q2

Infinity (INFI) posts narrower-than-expected loss in the second quarter of 2018 and provides update on pipeline candidate, IPI 549.

VRTX : 175.93 (+0.50%)
RCUS : 12.29 (+3.80%)
INFI : 2.07 (+4.55%)
BMY : 59.96 (+0.91%)
Infinity Pharmaceuticals Provides Company Update and Second Quarter 2018 Financial Results

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its second quarter 2018 financial results and provided an update on the company, including its progress with IPI-549, a first-in-class oral...

INFI : 2.07 (+4.55%)
Infinity Pharmaceuticals Appoints Samuel Agresta, M.D., M.P.H. as Chief Medical Officer

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced today that it has appointed Samuel Agresta, M.D., M.P.H., as Chief Medical Officer where he will oversee global clinical development and regulatory...

INFI : 2.07 (+4.55%)
Infinity Announces The Date Of Its Second Quarter 2018 Financial Results Conference Call And Webcast

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference call on Tuesday, August 7, 2018, at 4:30 p.m. ET to review its second quarter 2018 financial results and provide an update on the company....

INFI : 2.07 (+4.55%)
Free Technical Research on Insmed and Three More Biotech Equities

Stock Research Monitor: INFI, INVA, and INO

INVA : 14.02 (+1.96%)
INFI : 2.07 (+4.55%)
INO : 4.49 (+1.58%)
Infinity and Arcus Ink Deal for Two Triple Combo Studies

: Infinity Pharmaceuticals, Inc. (INFI) and Arcus Biosciences, Inc. (RCUS) sign a deal to evaluate two triple combination therapies in selected tumor types.

AGLE : 9.16 (-4.58%)
RCUS : 12.29 (+3.80%)
ANIP : 57.15 (-0.14%)
INFI : 2.07 (+4.55%)
Arcus Biosciences and Infinity Pharmaceuticals Announce Clinical Collaboration to Evaluate Lead Programs in Triple-Combination Studies

Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, and Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage...

RCUS : 12.29 (+3.80%)
INFI : 2.07 (+4.55%)
Is the Options Market Predicting a Spike in Infinity (INFI) Stock?

Investors in Infinity (INFI) need to pay close attention to the stock based on moves in the options market lately.

INFI : 2.07 (+4.55%)
New Research: Key Drivers of Growth for CNA Financial, AutoNation, Hess, Infinity Pharmaceuticals, Regulus Therapeutics, and Weyerhaeuser -- Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of CNA Financial Corporation (NYSE:CNA),...

WY : 34.30 (+1.12%)
CNA : 44.74 (-0.42%)
HES : 63.92 (+0.93%)
INFI : 2.07 (+4.55%)
RGLS : 0.26 (+31.31%)
AN : 46.00 (+0.44%)
Infinity Pharmaceuticals (INFI) Down 6.7% Since Earnings Report: Can It Rebound?

Infinity Pharmaceuticals (INFI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

INFI : 2.07 (+4.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More Share

Trade INFI with:

Business Summary

Infinity Pharmaceuticals, Inc. is an innovative cancer drug discovery and development company that is seeking to leverage its strength in small molecule drug technologies to discover, develop, and deliver to patients best-in-class medicines for the treatment of cancer and related conditions.

See More

Key Turning Points

2nd Resistance Point 2.21
1st Resistance Point 2.14
Last Price 2.07
1st Support Level 1.94
2nd Support Level 1.82

See More

52-Week High 3.75
Fibonacci 61.8% 2.67
Fibonacci 50% 2.34
Last Price 2.07
Fibonacci 38.2% 2.01
52-Week Low 0.93

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar